Novo Nordisk(US:NVO) Di Yi Cai Jing·2025-06-21 05:04Group 1 - The American College of Cardiology (ACC) has updated its guidelines, recommending that obese patients should prioritize the use of weight-loss medications to prevent heart disease, contrasting with previous guidelines that suggested lifestyle changes first [1] - ACC experts indicate that a weight loss of 10% is necessary to potentially reduce cardiovascular event risks, while a 15% weight loss may decrease cardiovascular-related mortality risks, with medication being the most effective method to achieve these goals [1] - Novo Nordisk reported at the American Diabetes Association (ADA) conference that higher doses of semaglutide can lead to an average weight reduction of 21% in obese patients, with one-third of participants losing 25% or more of their body weight [1] Group 2 - The FDA approved Novo Nordisk's semaglutide for weight loss in March last year, making it the first drug approved for preventing potentially fatal heart issues in overweight patients with heart disease [2] - The ACC emphasizes that insurance coverage uncertainty poses a significant barrier to treatment accessibility, calling for improvements in the availability of weight-loss therapies [2] - There are concerns among some doctors regarding the long-term health impacts of weight-loss medications, as current drugs may lead to indiscriminate weight loss, affecting both fat and muscle mass, which could impact quality of life [2] Group 3 - Numerous companies are actively engaged in developing next-generation weight-loss medications, focusing on strategies to reduce fat while preserving muscle mass [2] - Regeneron has released positive mid-stage clinical data, and Eli Lilly plans to present mid-stage data for its new weight-loss drug bimagrumab at the upcoming ADA conference, which aims to preserve muscle quality [2]